Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 337

1.

Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project.

Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, Adamkova V, Alicino C, Almyroudi MP, Atchade E, Azzini AM, Carannante N, Carnelutti A, Corcione S, Cortegiani A, Dimopoulos G, Dubler S, García-Garmendia JL, Girardis M, Cornely OA, Ianniruberto S, Kullberg BJ, Lagrou K, Le Bihan C, Luzzati R, Malbrain MLNG, Merelli M, Marques AJ, Martin-Loeches I, Mesini A, Paiva JA, Peghin M, Raineri SM, Rautemaa-Richardson R, Schouten J, Brugnaro P, Spapen H, Tasioudis P, Timsit JF, Tisa V, Tumbarello M, van den Berg CHSB, Veber B, Venditti M, Voiriot G, Wauters J, Montravers P.

Crit Care. 2019 Jun 14;23(1):219. doi: 10.1186/s13054-019-2497-3.

2.

Invasive Fungal Infection.

Lilienfeld-Toal MV, Wagener J, Einsele H, Cornely OA, Kurzai O.

Dtsch Arztebl Int. 2019 Apr 19;116(16):271-278. doi: 10.3238/arztebl.2019.0271.

3.

[Fungal infections].

Köhler P, Cornely OA, Vehreschild JJ.

Internist (Berl). 2019 May 22. doi: 10.1007/s00108-019-0618-3. [Epub ahead of print] Review. German.

PMID:
31119309
4.

Intensive care management of influenza-associated pulmonary aspergillosis.

Koehler P, Bassetti M, Kochanek M, Shimabukuro-Vornhagen A, Cornely OA.

Clin Microbiol Infect. 2019 May 16. pii: S1198-743X(19)30209-5. doi: 10.1016/j.cmi.2019.04.031. [Epub ahead of print] Review.

PMID:
31102782
5.

Baseline predictors influencing the prognosis of invasive aspergillosis in adults.

Koehler P, Salmanton-García J, Gräfe SK, Koehler FC, Mellinghoff SC, Seidel D, Steinbach A, Cornely OA.

Mycoses. 2019 May 7. doi: 10.1111/myc.12926. [Epub ahead of print]

PMID:
31066092
6.

Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis.

Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild MJGT, Bohlius J, Wisplinghoff H, Vehreschild JJ.

Clin Microbiol Infect. 2019 Apr 27. pii: S1198-743X(19)30202-2. doi: 10.1016/j.cmi.2019.04.024. [Epub ahead of print] Review.

PMID:
31039444
7.

Mould-reactive T cells for the diagnosis of invasive mould infection-A prospective study.

Steinbach A, Cornely OA, Wisplinghoff H, Schauss AC, Vehreschild JJ, Rybniker J, Hamprecht A, Richter A, Bacher P, Scheffold A, Koehler P.

Mycoses. 2019 Jul;62(7):562-569. doi: 10.1111/myc.12919. Epub 2019 May 23.

PMID:
31034691
8.

Triazole Antifungal Susceptibility Patterns among Aspergillus Species in Québec, Canada.

Cheng MP, Lawandi A, Lee TC, Dufresne PJ, Seidel D, Verweij PE, Cornely OA, Sheppard DC.

J Clin Microbiol. 2019 May 24;57(6). pii: e00404-19. doi: 10.1128/JCM.00404-19. Print 2019 Jun. No abstract available.

PMID:
30918044
9.

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.

Cornely OA, Vehreschild MJGT, Adomakoh N, Georgopali A, Karas A, Kazeem G, Guery B.

Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1187-1194. doi: 10.1007/s10096-019-03525-y. Epub 2019 Mar 25.

10.

Antifungal combinations in Mucorales: a microbiological perspective.

Schwarz P, Cornely OA, Dannaoui E.

Mycoses. 2019 Mar 4. doi: 10.1111/myc.12909. [Epub ahead of print] Review.

PMID:
30830980
11.

Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans.

Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, Röhmel J, Eschenhagen P, Grehn C, Seidel K, Rickerts V, Lozza L, Stervbo U, Nienen M, Babel N, Milleck J, Assenmacher M, Cornely OA, Ziegler M, Wisplinghoff H, Heine G, Worm M, Siegmund B, Maul J, Creutz P, Tabeling C, Ruwwe-Glösenkamp C, Sander LE, Knosalla C, Brunke S, Hube B, Kniemeyer O, Brakhage AA, Schwarz C, Scheffold A.

Cell. 2019 Mar 7;176(6):1340-1355.e15. doi: 10.1016/j.cell.2019.01.041. Epub 2019 Feb 21.

PMID:
30799037
12.

Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology.

Koehler P, Mellinghoff SC, Lagrou K, Alanio A, Arenz D, Hoenigl M, Koehler FC, Lass-Flörl C, Meis JF, Richardson M, Cornely OA.

J Antimicrob Chemother. 2019 Jun 1;74(6):1704-1712. doi: 10.1093/jac/dkz051.

PMID:
30770712
13.

Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent Clostridioides difficile infection.

Farowski F, Solbach P, Tsakmaklis A, Brodesser S, Cruz Aguilar MR, Cornely OA, Dettmer K, Higgins PG, Suerbaum S, Jazmati N, Oefner PJ, Vehreschild MJGT; German Clinical Microbiome Study Group (GCMSG).

Dig Liver Dis. 2019 Jan 26. pii: S1590-8658(19)30040-4. doi: 10.1016/j.dld.2019.01.012. [Epub ahead of print]

PMID:
30770201
14.

Combination Antimicrobial Therapy for Enterococcus faecalis Infective Endocarditis.

Koehler P, Jung N, Cornely OA, Rybniker J, Fätkenheuer G.

Clin Infect Dis. 2019 Feb 1. doi: 10.1093/cid/ciz054. [Epub ahead of print] No abstract available.

PMID:
30715308
15.

Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.

Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH.

Lancet Infect Dis. 2019 Mar;19(3):265-274. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29.

PMID:
30709665
16.

Corrigendum: Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?

Zoran T, Sartori B, Sappl L, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Lo Cascio G, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild JJ, Trovato L, Lewis RE, Segal E, Rath PM, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikan-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Uzun O, Roudbary M, de la Fuente S, Houbraken J, Risslegger B, Sabino R, Lass-Flörl C, Lackner M.

Front Microbiol. 2019 Jan 14;9:3245. doi: 10.3389/fmicb.2018.03245. eCollection 2018.

17.

Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®.

Seidel D, Meißner A, Lackner M, Piepenbrock E, Salmanton-García J, Stecher M, Mellinghoff S, Hamprecht A, Durán Graeff L, Köhler P, Cheng MP, Denis J, Chedotal I, Chander J, Pakstis DL, Los-Arcos I, Slavin M, Montagna MT, Caggiano G, Mares M, Trauth J, Aurbach U, Vehreschild MJGT, Vehreschild JJ, Duarte RF, Herbrecht R, Wisplinghoff H, Cornely OA.

Crit Rev Microbiol. 2019 Feb;45(1):1-21. doi: 10.1080/1040841X.2018.1514366. Epub 2019 Jan 10. Erratum in: Crit Rev Microbiol. 2019 Feb 18;:1.

PMID:
30628529
18.

Metadata Correction: Epidemiology of Surgical Site Infections With Staphylococcus aureus in Europe: Protocol for a Retrospective, Multicenter Study.

Mellinghoff SC, Vehreschild JJ, Liss BJ, Cornely OA.

JMIR Res Protoc. 2019 Jan 7;8(1):e10712. doi: 10.2196/10712.

19.

Food Intake Recruits Orosensory and Post-ingestive Dopaminergic Circuits to Affect Eating Desire in Humans.

Thanarajah SE, Backes H, DiFeliceantonio AG, Albus K, Cremer AL, Hanssen R, Lippert RN, Cornely OA, Small DM, Brüning JC, Tittgemeyer M.

Cell Metab. 2019 Mar 5;29(3):695-706.e4. doi: 10.1016/j.cmet.2018.12.006. Epub 2018 Dec 27.

PMID:
30595479
20.

EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management.

Spec A, Mejia-Chew C, Powderly WG, Cornely OA.

Open Forum Infect Dis. 2018 Nov 12;5(11):ofy299. doi: 10.1093/ofid/ofy299. eCollection 2018 Nov. Review.

21.

Case report: A fatal case of cryptococcosis in an immunocompetent patient due to Cryptococcus deuterogattii (AFLP6/VGII).

Bauer M, Wickenhauser C, Haak A, Pazaitis N, Siebolts U, Mawrin C, Strauss C, Rickerts V, Stoevesandt D, Cornely OA, Meis JF, Hagen F.

JMM Case Rep. 2018 Oct 23;5(10):e005168. doi: 10.1099/jmmcr.0.005168. eCollection 2018 Oct.

22.

A novel approach to candidemia? The potential role of checkpoint inhibition.

Mellinghoff SC, von Bergwelt-Baildon M, Schößer HA, Cornely OA.

Med Mycol. 2019 Feb 1;57(2):151-154. doi: 10.1093/mmy/myy089.

PMID:
30462325
23.

Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.

Basu A, Prabhu VS, Dorr MB, Golan Y, Dubberke ER, Cornely OA, Heimann SM, Pedley A, Xu R, Hanson ME, Marcella S.

Open Forum Infect Dis. 2018 Nov 15;5(11):ofy218. doi: 10.1093/ofid/ofy218. eCollection 2018 Nov.

24.

Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project.

Bassetti M, Scudeller L, Giacobbe DR, Lamoth F, Righi E, Zuccaro V, Grecchi C, Rebuffi C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S, Azoulay E, Blot SI, Cornely OA, Lass-Flörl C, Koehler P, Cuenca-Estrella M, de Lange DW, De Rosa FG, De Waele JJ, Dimopoulos G, Garnacho-Montero J, Hoenigl M, Kanj SS, Maertens J, Martin-Loeches I, Muñoz P, Kullberg BJ, Agvald-Ohman C, Poulakou G, Rello J, Sanguinetti M, Taccone FS, Timsit JF, Torres A, Vazquez JA, Calandra T; from the Study Group for Infections in Critically Ill Patients (ESGCIP) and the Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID); European Society of Intensive Care Medicine (ESICM); European Confederation of Medical Mycology (ECMM); Mycoses Study Group Education and Research Consortium (MSGERC).

Mycoses. 2019 Apr;62(4):310-319. doi: 10.1111/myc.12869. Epub 2019 Jan 22.

PMID:
30426598
25.

Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016.

Heimann SM, Vehreschild MJGT, Cornely OA, Heinz WJ, Grüner B, Silling G, Kessel J, Seidel D, Vehreschild JJ.

J Hosp Infect. 2019 Mar;101(3):339-346. doi: 10.1016/j.jhin.2018.11.003. Epub 2018 Nov 10.

PMID:
30423409
26.

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS.

Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1.

27.

Essentials in Candida bloodstream infection.

Mellinghoff SC, Cornely OA, Jung N.

Infection. 2018 Dec;46(6):897-899. doi: 10.1007/s15010-018-1218-1. Epub 2018 Sep 14. Review.

PMID:
30218311
28.

The role of medical mycology societies in combating invasive fungal infections in low- and middle-income countries: A Nigerian model.

Oladele RO, Osaigbovo II, Ayanlowo OO, Otu AA, Hoenigl M, Cornely OA, Chakrabarti A, Denning DW.

Mycoses. 2019 Jan;62(1):16-21. doi: 10.1111/myc.12845. Epub 2018 Oct 8. Review.

PMID:
30184285
29.
30.

Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.

Jenks JD, Reed SL, Seidel D, Koehler P, Cornely OA, Mehta SR, Hoenigl M.

Int J Antimicrob Agents. 2018 Nov;52(5):706-712. doi: 10.1016/j.ijantimicag.2018.08.005. Epub 2018 Aug 9.

PMID:
30099056
31.

Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together.

Hoenigl M, Gangneux JP, Segal E, Alanio A, Chakrabarti A, Chen SC, Govender N, Hagen F, Klimko N, Meis JF, Pasqualotto AC, Seidel D, Walsh TJ, Lagrou K, Lass-Flörl C, Cornely OA; European Confederation of Medical Mycology (ECMM).

Mycoses. 2018 Nov;61(11):885-894. doi: 10.1111/myc.12836. Epub 2018 Aug 28.

PMID:
30086186
32.

European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.

Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly J, Cordonnier C; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and; European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN) .

J Antimicrob Chemother. 2018 Dec 1;73(12):3221-3230. doi: 10.1093/jac/dky286.

PMID:
30085172
33.

PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis.

Baldin C, Soliman SSM, Jeon HH, Alkhazraji S, Gebremariam T, Gu Y, Bruno VM, Cornely OA, Leather HL, Sugrue MW, Wingard JR, Stevens DA, Edwards JE Jr, Ibrahim AS.

J Clin Microbiol. 2018 Sep 25;56(10). pii: e00746-18. doi: 10.1128/JCM.00746-18. Print 2018 Oct.

34.

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

Prabhu VS, Cornely OA, Golan Y, Dubberke ER, Heimann SM, Hanson ME, Liao J, Pedley A, Dorr MB, Marcella S.

Clin Infect Dis. 2017 Oct 1;65(7):1218-1221. doi: 10.1093/cid/cix523.

35.

Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.

Maertens J, Selleslag D, Heinz WJ, Saulay M, Rahav G, Giladi M, Aoun M, Kovanda L, Kaufhold A, Engelhardt M, Cornely OA, Herbrecht R, Ullmann AJ.

Mycoses. 2018 Nov;61(11):868-876. doi: 10.1111/myc.12831. Epub 2018 Aug 13.

PMID:
30035825
36.

Candida-Reactive T Cells for the Diagnosis of Invasive Candida Infection-A Prospective Pilot Study.

Koehler FC, Cornely OA, Wisplinghoff H, Schauss AC, Salmanton-Garcia J, Ostermann H, Ziegler M, Bacher P, Scheffold A, Alex R, Richter A, Koehler P.

Front Microbiol. 2018 Jun 22;9:1381. doi: 10.3389/fmicb.2018.01381. eCollection 2018.

37.

Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease.

Salzer HJF, Burchard G, Cornely OA, Lange C, Rolling T, Schmiedel S, Libman M, Capone D, Le T, Dalcolmo MP, Heyckendorf J.

Respiration. 2018;96(3):283-301. doi: 10.1159/000489501. Epub 2018 Jun 28.

38.

Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship.

Mellinghoff SC, Hartmann P, Cornely FB, Knauth L, Köhler F, Köhler P, Krause C, Kronenberg C, Kranz SL, Menon V, Müller H, Naendrup JH, Pützfeld S, Ronge A, Rutz J, Seidel D, Wisplinghoff H, Cornely OA.

Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1563-1571. doi: 10.1007/s10096-018-3285-8. Epub 2018 Jun 13.

PMID:
29948362
39.

EQUAL Aspergillosis Score 2018: An ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis.

Cornely OA, Koehler P, Arenz D, C Mellinghoff S.

Mycoses. 2018 Nov;61(11):833-836. doi: 10.1111/myc.12820. Epub 2018 Jul 13.

PMID:
29944740
40.

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.

Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Žák P, Craig MD, Papanicolaou GA, Velez JD, Panse J, Hurtado K, Fernsler DA, Stek JE, Pang L, Su SC, Zhao Y, Chan ISF, Kaplan SS, Parrino J, Lee I, Popmihajlov Z, Annunziato PW, Arvin A; V212 Protocol 001 Trial Team.

Lancet. 2018 May 26;391(10135):2116-2127. doi: 10.1016/S0140-6736(18)30631-7. Epub 2018 May 24.

PMID:
29856344
41.

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.

Cornely OA, Watt M, McCrea C, Goldenberg SD, De Nigris E.

J Antimicrob Chemother. 2018 Sep 1;73(9):2529-2539. doi: 10.1093/jac/dky184.

42.

A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases.

Revankar SG, Baddley JW, Chen SC, Kauffman CA, Slavin M, Vazquez JA, Seas C, Morris MI, Nguyen MH, Shoham S, Thompson GR 3rd, Alexander BD, Simkins J, Ostrosky-Zeichner L, Mullane K, Alangaden G, Andes DR, Cornely OA, Wahlers K, Lockhart SR, Pappas PG.

Open Forum Infect Dis. 2017 Sep 26;4(4):ofx200. doi: 10.1093/ofid/ofx200. eCollection 2017 Fall.

43.

How to prophylax against invasive fungal infections in adult ALL? An unmet need.

Cornely OA, Kontoyiannis DP.

Mycoses. 2018 Sep;61(9):646-649. doi: 10.1111/myc.12786. Epub 2018 Jun 13.

PMID:
29693737
44.

Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, Heinz WJ, Hentrich M, Maschmeyer G, Mayer K, Sandherr M, Silling G, Ullmann A, Vehreschild MJGT, von Lilienfeld-Toal M, Wolf HH, Lehners N; German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO).

Ann Oncol. 2018 Jun 1;29(6):1354-1365. doi: 10.1093/annonc/mdy117.

45.

Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients.

Postina P, Skladny J, Boch T, Cornely OA, Hamprecht A, Rath PM, Steinmann J, Bader O, Miethke T, Dietz A, Merker N, Hofmann WK, Buchheidt D, Spiess B.

Front Microbiol. 2018 Mar 27;9:555. doi: 10.3389/fmicb.2018.00555. eCollection 2018.

46.

Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis.

Heimann SM, Biehl LM, Vehreschild JJ, Franke B, Cornely OA, Vehreschild MJGT.

Am J Infect Control. 2018 Sep;46(9):992-997. doi: 10.1016/j.ajic.2018.03.006. Epub 2018 Apr 13.

PMID:
29661631
47.

Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?

Zoran T, Sartori B, Sappl L, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Cascio GL, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild JJ, Trovato L, Lewis RE, Segal E, Rath PM, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikan-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Uzun O, Roudbary M, de la Fuente S, Houbraken J, Risslegger B, Lass-Flörl C, Lackner M.

Front Microbiol. 2018 Mar 28;9:516. doi: 10.3389/fmicb.2018.00516. eCollection 2018. Erratum in: Front Microbiol. 2019 Jan 14;9:3245.

48.

Isavuconazole for treatment of rare invasive fungal diseases.

Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, Lu Q, Lademacher C, Perfect JR, Oren I, Schmitt-Hoffmann AH, Giladi M, Marty FM, Rahav G.

Mycoses. 2018 Aug;61(8):518-533. doi: 10.1111/myc.12778.

PMID:
29611246
49.

Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.

Marty FM, Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, Lu Q, Lademacher C, Oren I, Schmitt-Hoffmann AH, Giladi M, Rahav G, Perfect JR.

Mycoses. 2018 Jul;61(7):485-497. doi: 10.1111/myc.12777. Epub 2018 Apr 26.

PMID:
29611227
50.

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.

Perfect JR, Cornely OA, Heep M, Ostrosky-Zeichner L, Mullane KM, Maher R, Croos-Dabrera R, Lademacher C, Engelhardt M, Chen C, Marty FM.

Mycoses. 2018 Jul;61(7):420-429. doi: 10.1111/myc.12769. Epub 2018 Apr 19. Review.

PMID:
29570857

Supplemental Content

Loading ...
Support Center